[ad_1]
Third Avenue Administration, a New York Metropolis-based funding agency, printed its fourth-quarter 2025 investor letter for the “Third Avenue Small-Cap Worth Fund. ” A replica of the letter is on the market for obtain right here. Within the quarter, the Fund returned 4.62%, outperforming the MSCI USA Small-Cap Worth Index (the “Index”), which gained 3.13%. For the 12 months 2025, the Fund delivered a 14.04% return, surpassing the ten.80% return of the index. The Fund primarily invests in publicly traded corporations with boards of administrators, generally managed by people or households, and administration groups that function independently from the Fund. Reviewing 2025, the agency is happy with the Fund’s efficiency, operational success, and shareholder worth creation, and is optimistic about 2026. Please evaluate the Fund’s high 5 holdings to achieve insights into their key picks for 2025.
In its fourth-quarter 2025 investor letter, Third Avenue Small-Cap Worth Fund highlighted Collegium Pharmaceutical, Inc. (NASDAQ:COLL) as considered one of its main contributors. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is a specialty pharmaceutical firm that focuses on growing medicines for ache administration. On March 09, 2026, Collegium Pharmaceutical, Inc. (NASDAQ:COLL) inventory closed at $37.27 per share. One-month return of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was -20.28%, and its shares gained 24.27% over the previous 52 weeks. Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has a market capitalization of $1.183 billion.
Third Avenue Small-Cap Worth Fund said the next relating to Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in its fourth quarter 2025 investor letter:
“U.S. ache treatment specialist, Collegium Pharmaceutical, Inc. (NASDAQ:COLL), additionally generated a robust efficiency contribution within the quarter after producing document quarterly income and disclosing improved working earnings steerage and a brand new share repurchase authorization.”
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) is just not on our record of 40 Most In style Shares Amongst Hedge Funds Heading Into 2026. In accordance with our database, 34 hedge fund portfolios held Collegium Pharmaceutical, Inc. (NASDAQ:COLL) on the finish of the fourth quarter, up from 27 within the earlier quarter. Whereas we acknowledge the potential of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) as an funding, we consider sure AI shares supply better upside potential and carry much less draw back threat. When you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
[ad_2]
